By listing device patents that do not even mention the active ingredient, innovators can trigger a 30-month stay on generic competition
Incidences of dysesthesia occurred in 5.1%, 12.3%, and 12.5% of patients treated with retatrutide 4 mg, 9 mg, and 12 mg, respectively, compared with 0.9% with placebo, and incidences of urinary tract infections occurred in 7.5%, 8.8%, and 8.4% of patients treated with retatrutide 4 mg, 9 mg, and 12 mg, respectively, compared with 5.3% with placebo
GLP-1 receptor agonists are transforming weight loss medicine, with semaglutide (Ozempic/Wegovy) delivering 12% weight loss and tirzepatide (Mounjaro/Zepbound) achieving 18% in clinical trials
Our job is to restore that system through food, movement, sleep, and stress management before or alongside any medication." GLP-1 is secreted primarily by L-cells in the small intestine and colon
Regular communication with healthcare providers and consistent monitoring of pharmacy stocks are key strategies in navigating this shortage